Axon Enterprise (NASDAQ:AXON) PT Raised to $310.00 at Morgan Stanley

Axon Enterprise (NASDAQ:AXON) had its target price boosted by Morgan Stanley from $285.00 to $310.00 in a research report released on Friday, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.

Several other research analysts also recently issued reports on the company. StockNews.com downgraded Axon Enterprise from a buy rating to a hold rating in a research note on Thursday, March 14th. TheStreet downgraded Axon Enterprise from a b rating to a c+ rating in a research note on Tuesday, February 27th. Argus started coverage on Axon Enterprise in a research note on Wednesday, March 13th. They set a buy rating and a $380.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an overweight rating in a research report on Thursday, April 11th. Finally, Barclays lifted their price objective on Axon Enterprise from $296.00 to $308.00 and gave the stock an overweight rating in a research report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Axon Enterprise presently has an average rating of Moderate Buy and a consensus target price of $314.91.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $308.23 on Friday. The firm’s fifty day moving average price is $303.45 and its 200 day moving average price is $260.90. Axon Enterprise has a 1-year low of $175.37 and a 1-year high of $329.87. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. The firm has a market cap of $23.26 billion, a price-to-earnings ratio of 134.01 and a beta of 0.93.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.29. The company had revenue of $432.14 million during the quarter, compared to the consensus estimate of $418.97 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. On average, sell-side analysts expect that Axon Enterprise will post 2.44 EPS for the current year.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Planned Solutions Inc. purchased a new stake in Axon Enterprise in the 1st quarter valued at about $366,000. UMB Bank n.a. grew its holdings in Axon Enterprise by 3,924.5% in the 1st quarter. UMB Bank n.a. now owns 17,869 shares of the biotechnology company’s stock valued at $5,591,000 after buying an additional 17,425 shares during the period. YHB Investment Advisors Inc. purchased a new stake in Axon Enterprise in the 1st quarter valued at about $125,000. SYSTM Wealth Solutions LLC grew its holdings in Axon Enterprise by 2,359.5% in the 1st quarter. SYSTM Wealth Solutions LLC now owns 2,066 shares of the biotechnology company’s stock valued at $646,000 after buying an additional 1,982 shares during the period. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in Axon Enterprise in the 1st quarter valued at about $442,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.